Screener
UroGen Pharma URGN Net Income
Discontinued — last reported Q2 '26
Net Income at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest and other income, net | 599 | 1,299 | 1,207 | 3,413 |
| Loss before income taxes | (8,722) | (48,925) | (37,068) | (92,376) |
| Income tax expense | (5,629) | (1,015) | (857) | (1,407) |
| Net loss | $(14,351) | $(49,940) | $(37,925) | $(93,783) |
| Statements of comprehensive loss | ||||
| Net loss | $(14,351) | $(49,940) | $(37,925) | $(93,783) |
| Other comprehensive loss | ||||
| Unrealized loss on investments | (10) | (8) | (21) | (50) |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's net income?
- UroGen Pharma (URGN) reported net income of -$14.35M in Q2 2026.
- How has UroGen Pharma's net income changed year-over-year?
- UroGen Pharma's net income increased by 71.3% year-over-year, from -$49.94M to -$14.35M.
- What is the long-term trend for UroGen Pharma's net income?
- Over 4 years (2021 to 2025), UroGen Pharma's net income has grown at a 8.5% compound annual growth rate (CAGR), from -$110.82M to -$153.49M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about UroGen Pharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude